Back to funds
View filing
GILEAD SCIENCES, INC.
institutionalUpdated 16 days agoManaged by Gilead Sciences, Inc. • Latest filing Q3 2026
Portfolio value
$1.5B
Q3 2026
Filings
5
Quarterly 13F history
Top-10 concentration
100.0%
Weight of largest holdings
Annualized return
-18.3%
Implied from 13F holdings
Portfolio value history
13F-disclosed portfolio value over 5 quarters
Show data table
| Period | Portfolio value |
|---|---|
| Q3 2025 | $1.8B |
| Q4 2025 | $1.9B |
| Q1 2026 | $2.1B |
| Q2 2026 | $1.6B |
| Q3 2026 | $1.5B |
Top holdings
5 positions as of Q3 2026
| # | Stock | Value | Shares | % Portfolio | Change |
|---|---|---|---|---|---|
| 1 | $811.7M | 31.42M | 55.45% | Unchanged | |
| 2 | $501.3M | 16.71M | 34.24% | Unchanged | |
| 3 | $116.9M | 4.98M | 7.99% | Unchanged | |
| 4 | ? N/A Kyverna Therapeutics Inc. | $28.1M | 4.13M | 1.92% | Unchanged |
| 5 | ? N/A Xilio Therapeutics Inc. | $5.9M | 650.4K | 0.40% | Unchanged |